Plandai Biotech Stock Market Outlook
About 67% of Plandai Biotech's investor base is looking to short. The analysis of overall sentiment of trading Plandai Biotech pink sheet suggests that many investors are alarmed at this time. Plandai Biotech's investing sentiment shows overall attitude of investors towards Plandai Biotech.
Comfort Level 33
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Plandai Biotech's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Plandai Biotech.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentWaiting |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Plandai Biotech is 'Strong Sell'. The recommendation algorithm takes into account all of Plandai Biotech's available fundamental, technical, and predictive indicators you will find on this site.
Execute Plandai Biotech Advice
The Plandai recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Plandai Biotech. Macroaxis does not own or have any residual interests in Plandai Biotech or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Plandai Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
For the selected time horizon Plandai Biotech has a Return On Asset of -0.21, Operating Margin of (12.22) %, Current Valuation of 236.87 K, Shares Outstanding of 263.19 M, Price To Earning of (0.32) X and Price To Sales of 1.04 XWe provide trade recommendations to complement the recent expert consensus on Plandai Biotech. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Plandai Biotech is not overpriced, please check all Plandai Biotech fundamentals, including its revenue, earnings per share, net asset, as well as the relationship between the total debt and retained earnings . As Plandai Biotech appears to be a penny stock we also advise to check out its revenue numbers.
Plandai Biotech Trading Alerts and Improvement Suggestions
| Plandai Biotech is way too risky over 90 days horizon | |
| Plandai Biotech has some characteristics of a very speculative penny stock | |
| Plandai Biotech appears to be risky and price may revert if volatility continues | |
| Plandai Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Plandai Biotech currently holds 50.53 K in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Plandai Biotech has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Plandai Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Plandai Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Plandai Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Plandai to invest in growth at high rates of return. When we think about Plandai Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 411.99 K. Net Loss for the year was (4.01 M) with loss before overhead, payroll, taxes, and interest of (768.91 K). | |
| Plandai Biotech currently holds about 7.96 K in cash with (1.1 M) of positive cash flow from operations. |
Plandai Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Plandai Biotech or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Plandai Biotech's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Plandai pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 130.79 | |
Ir | Information ratio | 0.00 |
Plandai Biotech Volatility Alert
At this time Plandai Biotech exhibits very low volatility. You can indeed make money on Plandai instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Plandai Biotech Fundamentals Vs Peers
Comparing Plandai Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Plandai Biotech's direct or indirect competition across all of the common fundamentals between Plandai Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Plandai Biotech or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Plandai Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Plandai Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Plandai Biotech to competition |
| Fundamentals | Plandai Biotech | Peer Average |
| Return On Asset | -0.21 | -0.14 |
| Operating Margin | (12.22) % | (5.51) % |
| Current Valuation | 236.87 K | 16.62 B |
| Shares Outstanding | 263.19 M | 571.82 M |
| Price To Earning | (0.32) X | 28.72 X |
| Price To Sales | 1.04 X | 11.42 X |
| Revenue | 411.99 K | 9.43 B |
| Gross Profit | (768.91 K) | 27.38 B |
| EBITDA | (2.1 M) | 3.9 B |
| Net Income | (4.01 M) | 570.98 M |
| Cash And Equivalents | 7.96 K | 2.7 B |
| Total Debt | 50.53 K | 5.32 B |
| Debt To Equity | 0.95 % | 48.70 % |
| Current Ratio | 0.01 X | 2.16 X |
| Book Value Per Share | (0.05) X | 1.93 K |
| Cash Flow From Operations | (1.1 M) | 971.22 M |
| Earnings Per Share | (0.03) X | 3.12 X |
| Number Of Employees | 250 | 18.84 K |
| Beta | -1.3 | -0.15 |
| Market Capitalization | 276.35 K | 19.03 B |
| Total Asset | 6.82 M | 29.47 B |
| Retained Earnings | (39.32 M) | 9.33 B |
| Working Capital | (15.26 M) | 1.48 B |
| Current Asset | 176 K | 9.34 B |
| Current Liabilities | 15.44 M | 7.9 B |
| Z Score | -6.4 | 8.72 |
| Net Asset | 6.82 M |
About Plandai Biotech Buy or Sell Advice
When is the right time to buy or sell Plandai Biotech? Buying financial instruments such as Plandai Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Plandai Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate Bonds Funds Thematic Idea Now
Corporate Bonds Funds
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Plandai Pink Sheet
Plandai Biotech financial ratios help investors to determine whether Plandai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Plandai with respect to the benefits of owning Plandai Biotech security.